<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58814">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054234</url>
  </required_header>
  <id_info>
    <org_study_id>ADVISE France</org_study_id>
    <nct_id>NCT02054234</nct_id>
  </id_info>
  <brief_title>ADenoVirus Initiative Study in Epidemiology in France</brief_title>
  <official_title>Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NicOx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NicOx</source>
  <oversight_info>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to assess the characteristics and frequency of adenovirus
      conjunctivitis in a population of male and female patients from one year of age who present
      signs and symptoms of acute conjunctivitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological, prospective, open, multicentric trial in patients suffering from acute
      conjunctivitis who will undergo a rapid diagnostic test for adenoviral conjunctivitis at the
      time of their visit to the ophthalmologist office, at the emergency room or during
      hospitalization. This epidemiological study will include approximately 500 patients in
      France. The planned duration of the study is one year from the first patient visit to the
      last patient visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Frequency of patients with adenovirus conjunctivitis</measure>
    <time_frame>During the visit to the ophthalmologist before and just after the AdenoPlus® test done on the same day (one visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The  percentage of patients with adenovirus conjunctivitis documented by a positive AdenoPlus® test over the tested population of male and female patients who present signs and symptoms of acute conjunctivitis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Seasonality and geographic repartition observed.</measure>
    <time_frame>During the visit to the ophthalmologist before and just after the AdenoPlus® test done on the same day (one visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of patients with adenovirus conjunctivitis who visited the ophthalmologist in spring, summer, autumn and winter and their geographic area (e.g. by hospital, by area).</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical profiles of the patients</measure>
    <time_frame>During the visit to the ophthalmologist before and just after the AdenoPlus® test done on the same day (one visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of each eye signs and symptoms, the mean duration of the disease for both the patients with positive and negative AdenoPlus® tests, the number or follow-up visit done and the correlation between the initial diagnosis (before AdenoPlus® test results) and the final diagnosis (post AdenoPlus® test results).</description>
  </other_outcome>
  <other_outcome>
    <measure>Resource utilization during the treatment and evaluation of the costs</measure>
    <time_frame>On day 1: at least once during the single visit  to the ophthalmologist and if any also during the follow-up visit(s)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimation of resource utilized during course of treatment (use of drugs, number of visits done by the patient…), and associated costs (which would be calculated by applying unit costs to resource use).</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient/parent absenteeism linked to this disease.</measure>
    <time_frame>On day 1: at least once during the single visit to the ophthalmologist and if any also during the follow-up visit(s)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days out of work and/or out of school linked to this disease.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety assessment</measure>
    <time_frame>On day 1: at least once during the single visit to the ophthalmologist and if any also during the follow-up visit(s)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of adverse incidents (AIs) and events that are of significant (SEs) reported to Nicox</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Viral Conjunctivitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any female and male patients from one year of age with signs and symptoms of acute
        conjunctivitis either seen during ophthalmology consultations or who are in the emergency
        room or hospitalized, can be enrolled in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female patients of at least one year of age presenting acute (for less than 7
             days) conjunctivitis signs and symptoms.

          -  Patient or / and legal representative (if patient below 18 years of age) must be able
             to provide oral consent for the collection and treatment of the questionnaire data.

          -  No history of hypersensitivity to corn starch, talcum powder or Dacron (sampling
             fleece components).

        Exclusion Criteria:

          -  Current use or having received (within the last 7 days) local antiviral therapies
             such as povidone iodine or ganciclovir, or topical steroids or immunomodulators such
             as cyclosporine which may interfere with the test result.

          -  Previous enrolment in the present study.

          -  Any direct involvement with the study conduct at site or any family link with study
             site staff.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Tuil</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHNO Des Quinze-Vingts</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brigitte Duquesroix, MD</last_name>
    <phone>33 (0)4 97 24 53 00</phone>
    <email>duquesroix@nicox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Schweitzer, MD</last_name>
      <email>cedric.schweitzer@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Cedric Schweitzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU BREST- Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Tanguy, MD</last_name>
      <email>christine.tanguy@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Tanguy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice Cochener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Kremlin-Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédèrique L'Huillier</last_name>
      <email>Frederique.lhuillier@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Labetoulle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Hoffart, MD</last_name>
      <email>louis.hoffart@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Louis Hoffart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Saint Roch</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Baillif-Gostoli, MD</last_name>
      <email>baillif-gostoli.s@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Baillif-Gostoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Gastaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustapha Benchaboune, MD</last_name>
      <email>ben@solsol.org</email>
    </contact>
    <investigator>
      <last_name>Eric Tuil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chérif Titah, MD</last_name>
      <email>smctitah@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Cochereau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chérif Titah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier La Pitié Salpêtrière-Charles Foix</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Fardeau, MD</last_name>
      <email>christine.fardeau@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Fardeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Girard, MD</last_name>
      <email>brigitte.girard@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Girard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan Bourcier, MD</last_name>
      <email>tristan.bourcier@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Tristan Bourcier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie PISELLA</last_name>
      <email>mpisella@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Pisella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>January 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenoviral conjunctivitis diagnosed with AdenoPlus™ Test</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Viral</mesh_term>
    <mesh_term>Conjunctivitis, Inclusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
